Therefore, the results of this analysis suggest that hepatic fibrosis may be improved 24 weeks after treatment with luseogliflozin in diabetic patients with ALT > 30 U/L and with FIB-4 index > 1.3. This evidence concerns the gene GPT and Hepatic fibrosis.